Spectral Med Inc (EDT) - Total Assets

Latest as of September 2025: CA$8.12 Million CAD ≈ $5.88 Million USD

Based on the latest financial reports, Spectral Med Inc (EDT) holds total assets worth CA$8.12 Million CAD (≈ $5.88 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EDT total equity for net asset value and shareholders' equity analysis.

Spectral Med Inc - Total Assets Trend (1992–2024)

This chart illustrates how Spectral Med Inc's total assets have evolved over time, based on quarterly financial data.

Spectral Med Inc - Asset Composition Analysis

Current Asset Composition (December 2024)

Spectral Med Inc's total assets of CA$8.12 Million consist of 83.8% current assets and 16.2% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 56.2%
Accounts Receivable CA$451.00K 8.5%
Inventory CA$229.00K 4.3%
Property, Plant & Equipment CA$687.00K 12.9%
Intangible Assets CA$175.00K 3.3%
Goodwill CA$0.00 0.0%

Asset Composition Trend (1992–2024)

This chart illustrates how Spectral Med Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Spectral Med Inc.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Spectral Med Inc's current assets represent 83.8% of total assets in 2024, an increase from 82.2% in 1992.
  • Cash Position: Cash and equivalents constituted 56.2% of total assets in 2024, down from 64.4% in 1992.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1992.
  • Asset Diversification: The largest asset category is property, plant & equipment at 12.9% of total assets.

Spectral Med Inc Competitors by Total Assets

Key competitors of Spectral Med Inc based on total assets are shown below.

Company Country Total Assets
Sonic Healthcare Ltd
AU:SHL
Australia AU$17.03 Billion
Eurofins-Cerep SA
PA:ALECR
France €84.58 Million
Inoviq Ltd
AU:IIQ
Australia AU$24.52 Million
Bcal Diagnostics Ltd
AU:BDX
Australia AU$7.17 Million
Imagion Biosystems Ltd
AU:IBX
Australia AU$932.48K
Integral Diagnostics Ltd
AU:IDX
Australia AU$1.43 Billion
Australian Clinical Labs Ltd
AU:ACL
Australia AU$562.50 Million
Monash Ivf Group Ltd
AU:MVF
Australia AU$510.21 Million

Spectral Med Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.11 0.22 2.34
Quick Ratio 0.10 0.21 2.22
Cash Ratio 0.00 0.00 0.00
Working Capital CA$-60.12 Million CA$-26.63 Million CA$3.90 Million

Spectral Med Inc - Advanced Valuation Insights

This section examines the relationship between Spectral Med Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 49.87
Latest Market Cap to Assets Ratio 53.47
Asset Growth Rate (YoY) 2.1%
Total Assets CA$5.32 Million
Market Capitalization $284.46 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Spectral Med Inc's assets at a significant premium (53.47x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: Spectral Med Inc's assets grew by 2.1% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Spectral Med Inc (1992–2024)

The table below shows the annual total assets of Spectral Med Inc from 1992 to 2024.

Year Total Assets Change
2024-12-31 CA$5.32 Million
≈ $3.85 Million
+2.09%
2023-12-31 CA$5.21 Million
≈ $3.77 Million
-56.56%
2022-12-31 CA$12.00 Million
≈ $8.68 Million
+3.82%
2021-12-31 CA$11.55 Million
≈ $8.36 Million
+41.55%
2020-12-31 CA$8.16 Million
≈ $5.90 Million
+103.77%
2019-12-31 CA$4.01 Million
≈ $2.90 Million
-42.58%
2018-12-31 CA$6.98 Million
≈ $5.05 Million
+100.89%
2017-12-31 CA$3.47 Million
≈ $2.51 Million
-51.08%
2016-12-31 CA$7.10 Million
≈ $5.14 Million
-16.07%
2015-12-31 CA$8.46 Million
≈ $6.12 Million
-28.69%
2014-12-31 CA$11.86 Million
≈ $8.58 Million
+25.68%
2013-12-31 CA$9.44 Million
≈ $6.83 Million
-25.01%
2012-12-31 CA$12.59 Million
≈ $9.10 Million
-39.05%
2011-12-31 CA$20.65 Million
≈ $14.94 Million
+19.40%
2010-12-31 CA$17.30 Million
≈ $12.51 Million
+243.70%
2009-12-31 CA$5.03 Million
≈ $3.64 Million
-28.98%
2008-12-31 CA$7.08 Million
≈ $5.13 Million
-11.22%
2007-12-31 CA$7.98 Million
≈ $5.77 Million
-14.52%
2006-12-31 CA$9.34 Million
≈ $6.75 Million
-19.23%
2005-12-31 CA$11.56 Million
≈ $8.36 Million
-25.82%
2004-12-31 CA$15.58 Million
≈ $11.27 Million
-20.94%
2003-12-31 CA$19.71 Million
≈ $14.26 Million
+40.34%
2002-12-31 CA$14.04 Million
≈ $10.16 Million
-22.30%
2001-12-31 CA$18.07 Million
≈ $13.07 Million
+34.38%
2000-12-31 CA$13.45 Million
≈ $9.73 Million
-16.99%
1999-12-31 CA$16.20 Million
≈ $11.72 Million
-27.35%
1998-12-31 CA$22.30 Million
≈ $16.13 Million
-26.40%
1997-12-31 CA$30.30 Million
≈ $21.92 Million
-28.71%
1996-12-31 CA$42.50 Million
≈ $30.74 Million
+38.89%
1995-12-31 CA$30.60 Million
≈ $22.14 Million
-25.18%
1994-12-31 CA$40.90 Million
≈ $29.59 Million
+143.45%
1993-12-31 CA$16.80 Million
≈ $12.15 Million
+273.33%
1992-12-31 CA$4.50 Million
≈ $3.26 Million
--

About Spectral Med Inc

TO:EDT Canada Diagnostics & Research
Market Cap
$284.46 Million
CA$393.23 Million CAD
Market Cap Rank
#15183 Global
#458 in Canada
Share Price
CA$1.36
Change (1 day)
+0.74%
52-Week Range
CA$0.79 - CA$1.75
All Time High
CA$1.89
About

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device … Read more